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genes have evolved to protect against colonial (vascular)
fusion and parasitic stem cells by restricting germline
parasitism to kin; fester encodes their receptors.
Nyholm et al. offer many alternative explanations for
the role of fester in histocompatibility. One interpreta-
tion is that the products of fester are activating recep-
tors, which in turn alert colonies that are in contact with
another individual. Other observations are more consis-
tent with fester encoding inhibitory receptors. The au-
thors draw loose analogies to Natural Killer (NK) cells
in which self-recognition would prevent a rejection
(clearly, the system is not sensing nonself because
fusion occurs if one allele is shared). However, at the
structural level, NK recognition is mediated by members
of the immunoglobulin superfamily or by lectins, neither
of which bear substantial homology to the products of
the fester locus. The authors point out that the predicted
utilization of secreted and transmembrane forms dis-
tances fester from NK receptors. However, the complex
differential processing of fester is to a limited degree
reminiscent of NK receptors, leading to speculation
here that the splice variants create different avidity pro-
files and contribute to both species- and individual-
specific discrimination of FuHC polymorphisms.
Although the analogy of Botryllus colonial rejection to
mammalian immunity may provide comfortable familiar-
ity, interpretation of the fester-FuHC relationship in the
context of vertebrate immunity, particularly a process
as pleiomorphic as NK function, may well not be possi-
ble. The complexities of such interpretations, based on
phenomenology and not necessarily analogous at the
molecular level, are becoming abundantly clear in stud-
ies of other immune phenomena across broad phyloge-
netic boundaries (Litman et al., 2005). It may be more in-
sightful to consider the FuHC-fester product interaction
as a basal characteristic of cellular recognition to which
various aspects of mammalian immunity relate, rather
than to try interpreting allograft recognition in Botryllus
within the context of mammalian transplantation biol-
ogy. Functional dissection of the effector and genetic
regulatory circuits in Botryllus, which is where this work
likely is headed, may well lead to a better understanding
of the underlying basis for allorecognition or, at the very
least, a far better understanding of how self is pre-
served. Such fundamental answers will not be easily
forthcoming, but when they do emerge, promise to be
of major importance. It is evident here that these inves-
tigators are well on their way to this next level.
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15Migratory Dendritic Cells:
Sometimes Simply Ferries?
In this issue, Allan et al. (2006) conclude that trans-
port of herpes-virus antigens to lymph nodes by
dendritic cells is crucial for antiviral immunity, but mi-
grating DCs do not present herpes antigens to CD8+
lymphocytes.
Although the migration of antigen-bearing dendritic cells
(DCs) to draining lymph nodes is known to be critical for
the induction of adaptive immune responses to contact
sensitizers, the requirement for antigen-bearing DC mo-
bilization to lymph nodes to initiate antiviral immunity has
been unclear. A new study from the laboratories of
W. Heath and F. Carbone in this issue (Allan et al., 2006) di-
rectly examines the role of DC migration in the inductionof CD8+ T cell-mediated immunity to herpes simplex vi-
rus (HSV) after skin infection. The work concludes that
DC migration is indeed needed for the development of
CD8+ T responses to HSV, but surprisingly, a role for mi-
gratory antigen-bearing DCs beyond ferrying the antigen
to the lymph node was not apparent. That is, the authors
were unable to detect antigen presentation of HSV to
CD8+ T cells by the migratory DCs. Instead, antigen
was exclusively cross-presented by CD8a+ DCs that ap-
parently were previously resident in the lymph node. It
seems that migratory DCs ferry viral antigens to the
lymph node and immediately transfer the antigens to
CD8a+ DCs for cross-presentation (Figure 1). Whereas
the transfer of antigens from migratory to ‘‘resident’’
DCs was earlier established by K. Inaba et al. (Inaba
et al., 1998) and confirmed by others (Belz et al., 2004),
the conclusion that migratory DCs mediate not even
a part of the presentation to CD8+ T cells is remarkable.
However, these findings may not be generally applicable
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16Figure 1. DCs Team up against Herpes Virus
Herpes-virus antigens are transported by DCs to lymph nodes for presentation to T cells. Blocking DC migration with DP1 agonists or DNFB
pretreatment greatly reduces HSV CTL priming (left lymph node schematic). When migration of antigen-transporting DCs occurs, migratory
DCs play no role in presenting antigen to CD8+ T cells. Instead, transfer of antigen from the migrating DC population to presentation-competent
CD8a+ DCs occurs. Antigen transfer may result from rapid death of the migratory DC and subsequent engulfment by CD8a+ DCs (A). In this
scenario, the DC that presents to CD4+ helper T cells is unknown. In another possible scenario (B), migratory DCs present antigen strictly to
CD4+ helper T cells and transfer antigen to CD8a+ DCs for CD8+ T cells. This scenario would nicely merge the present findings with previous work
that examined DCs that stimulate CD4+ T cells during HSV infection (Zhao et al., 2003). A third population of DCs, the plasmacytoid DCs, plays
a critical supportive role (Yoneyama et al., 2005).to how the immune system initiates CTL responses
against viruses because another recent study concluded
that migratory skin DCs directly present lentivirus-
derived OVA to lymph node CD8+ T cells (He et al., 2006).
Prior publications from the same group and others
had indicated that Langerhans cells—specialized epi-
thelial DCs—did not present HSV to CD4+ or CD8+ T
cells (Allan et al., 2003; Zhao et al., 2003). Methods
used previously by Allan et al. (Allan et al., 2003) did
not distinguish whether other migratory DCs, such as
dermal DCs, or DCs already in lymph nodes presented
the herpes antigens. However, the group already knew
that CD8a+ DCs were the sole APCs inducing CD8+ T
cell responses (Allan et al., 2003). In general, CD8a+
DCs are not believed to derive from migratory DCs
from the periphery (Kamath et al., 2002). From that
perspective, the new data (Allan et al., 2006) could be
considered predictable. On the other hand, the same
group’s studies on a similar question in the lung
indicate that both migratory DCs and CD8a+ DCsparticipate in presenting influenza or HSV antigens for
CTL priming.
To assess whether migratory DCs were necessary and
sufficient for presenting HSV antigens to CD8+ HSV-spe-
cific T cells, the authors tested whether migratory DCs
were among lymph node DCs that presented antigen.
To do this, the authors employed a widely utilized
method wherein a fluorochrome is applied epicutane-
ously to trace skin DC migration. This assay labels a large
fraction of skin DCs, mainly of dermal origin (Kamath
et al., 2002). Infecting the skin with HSV while simulta-
neously applying fluorescent tracer epicutaneously to
track migratory DCs led to no overlap between the
fluor-labeled migratory DC population and DCs that
present antigen to HSV-restricted CD8+ T cells. The un-
derlying assumption is that the epicutaneously applied
fluor labels all skin-emigrating DCs. Although labeling
by this method is extensive, some DCs, such as the
CD11clo monocyte-derived DCs that efficiently transport
particulates to lymph nodes, are not fluor-labeled even
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simultaneously. Therefore, it remains possible that HSV-
transporting DCs with the capacity to present herpes
antigens were not among the fluor-labeled DCs. How-
ever, even the nonfluorescent CD11c+ draining lymph
node DCs did not present herpes antigens unless they
coexpressed CD8a. In contrast, a similar approach re-
vealed that fluorescent skin-derived migratory DCs
directly presented lentivirus-derived antigens to CD8+
T cells (He et al., 2006).
The main experiments to analyze the requirement for
migrating DCs in HSV infection took advantage of a syn-
thetic agonist of the prostaglandin D2 receptor DP1; this
agonist is known to potently interfere with DC migration
(Trottein et al., 2004). In line with the fact that the agonist
indeed blocked DC migration nearly completely, pre-
sentation of HSV viral antigens was markedly impeded,
suggesting that migratory DCs are needed for antiviral
CD8+ T cell responses. However, the DP1 agonist’s
other potentially critical suppressive effects, such as re-
duced IL-12 production, decreased DC maturation, or
effects on T cells (Trottein et al., 2004), were not elimi-
nated as causative. The authors used a second method
for blocking migration—infecting mice during a period
when prior treatment with DNFB causes a refractory
inhibition of migration and corresponds with a partial
depletion of peripheral DCs as a result of earlier stimu-
lation of migration—to help alleviate this concern. In
both cases where migration-inhibitory protocols were
used, the site of viral inoculation was removed 8 hr later,
so the authors took advantage of DP1 agonists and
DNFB to simply create a delay in migration from the in-
oculation site to determine if that would impact priming.
Indeed, this delay substantially decreased the magni-
tude of priming, in line with the conclusion that DC mi-
gration is required for viral transport to the lymph node.
Although it is reasonable to assume that the ap-
proaches used to block DC migration did just that, the
migrating DCs were never directly observed in this
work. The migration-blocking agents might have also
prevented the migration of other cell types that trans-
port the virus to the lymph node.
In light of the fact that HSV infection predisposes DCs
to apoptosis, rapid death in the lymph node could ex-
plain why there was no contribution to HSV antigen pre-
sentation by migratory DCs (Figure 1A). The tendency of
HSV to impair and kill DCs might also explain the impor-
tance of antigen transfer for cross-presentation of this vi-
rus, whereas, in contrast, toxicity of lentivirus is minimal,
such that it can be directly presented by migratory DCs
(He et al., 2006). It would be interesting to collect the mi-
gratory HSV antigen-bearing DCs prior to their arrival in
the lymph node, for example after migration from skin ex-
plants, to study their presentation capacity directly. It will
also be important to examine the role of the skin-migra-
tory DCs in presenting HSV to CD4+ T cells; work by Zhao
et al. in the vaginal mucosa has concluded that CD11b+
apparently migratory DCs, but not CD8a+ DCs, present
HSV antigens to CD4+ T cells (Zhao et al., 2003). If HSV-
bearing skin DCs largely die upon arrival in the lymph
node, then presentation to CD4+ T cells would also be
low to absent. So far, it is not yet clear whether the re-
sults of Zhao et al. (Zhao et al., 2003) and Allan et al.
(Allan et al., 2003; Allan et al., 2006) can be combined intoa unified model that applies to different tissues and infec-
tion protocols wherein migratory DCs that transport HSV
antigens present to CD4+ T cells, but not CD8+ T cells,
because the latter requires antigen transfer to CD8a+
DCs (Figure 1B). If the authors had been able to examine
CD4+ T cell responses, a much clearer picture of the se-
quence of events that occur could be assembled. Such
work might also make it possible to characterize and
directly observe the migratory DC itself and determine,
for example, if it was in fact among the FITC+ population
tracked as assumed.
Future studies are needed to investigate maturation
and formation of appropriate peptide/MHC complexes
within the presenting CD8a+ lymph node DCs in re-
sponse to the antigen transfer. Progress on this front
will require techniques to directly identify the antigen-
presenting fraction of DCs within the overall CD8a+ DC
population. Would uptake of HSV antigen-enriched ap-
optotic or live DCs, or DCs in the form of exosomes,
stimulate CD8a+ DC maturation through transfer of sig-
nals from the migratory DC? Or would maturation sig-
nals mainly derived from local cytokines or CD4+ T cells,
or both, help? Furthermore, what would be the point of
migratory DCs undergoing maturation—the major phe-
notype shift in which DCs increase their capacity to
prime T cells and downregulate their capacity for anti-
gen acquisition—if the findings of Allan et al. were widely
applicable (that is, if migratory DCs mainly act as ferries)
unless maturation-related molecules and signals were
also faithfully transferred and interpreted by the receiv-
ing, antigen-presenting DC? Or would the maturation of
migratory DCs remain important primarily to influence
the outcome of presentation to CD4+ T cells (Figure 1B)?
Antigen transfer by migratory DCs is not limited to in-
fectious diseases but has been more broadly observed
(Inaba et al., 1998). Use of nondegradable markers of an-
tigen together with biodegradable markers (congenic
surface proteins, for example) of migrating DCs permits
analysis of the rate of antigen transfer from adoptively
transferred, migratory DCs (Angeli et al., 2006). Almost
all bone-marrow-derived DCs migrating to lymph nodes
transfer even inert antigen to donor DCs within a few
days after they are deposited into skin, but fewer than
half have done so shortly upon arrival in the lymph node
(Angeli et al., 2006). It would be interesting to determine if
HSV infection accelerates the rate of this transfer and, if
so, whether it is due to DC apoptosis or ‘‘nibbling’’ from
live DCs. Advantages of antigen transfer from migratory
to lymph node resident DCs include potentially minimiz-
ing any deleterious effects of direct viral infection on the
presenting function of the migratory DC population, in-
creasing the number of presenting DCs and prolonging
antigen presentation. A related consequence of the
transfer is that it could allow the magnitude of antigen
presentation to amplify such that it is not directly propor-
tional to the magnitude of DC migration.
So how many DC subsets does it take to kick off
a CTL response to HSV? The answer seems to be at
least three: one to carry the virus (DC from the periph-
ery) (Allan et al., 2006), another to present it (lymph node
CD8a+ DCs) (Allan et al., 2003; Allan et al., 2006), and a
third to provide cytokine support (plasmacytoid DCs)
(Yoneyama et al., 2005) (Figure 1). From this scenario,
the point of there being so many subsets of DCs in the
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18immune system starts to make sense. To mount effec-
tive responses against tough pathogens, DC subsets
team up and work together.
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